Atea reports Q2 2026 results, cites C-BEYOND Phase 3 win in hepatitis C
Atea's HCV combination met its primary endpoint against Epclusa, and the company plans to file for FDA approval in the second quarter of 2027.
SEC filing
Latest
2 stories
Sign in